JBEI's Keasling Elected to National Academy of Inventors
JBEI's CEO Jay Keasling was among 170 new fellows, recognized by the National Academy of Investors for outstanding contributions to innovation in patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation.
The Economist Recognizes JBEI’s CEO Jay Keasling for Anti-Malarial Effort
On Sept. 10, The Economist announced JBEI’s CEO Jay Keasling as the winner of its 2014 Innovation Award in the Bioscience category. In addition to being JBEI’s CEO, Keasling is a Professor of Chemical Engineering at the University of California, Berkeley and Senior Faculty Scientist and Associate Lab Director at Berkeley Lab. He was recognized for his development of synthetic artemisinin used to treat malaria.
Keasling Wins 2014 Eni Award’s Renewable Energy Prize
Jay Keasling, CEO of the Joint BioEnergy Institute (JBEI), and pioneer in synthetic biology, has been honored as the recipient of the 2014 Renewable Energy Eni Award for his work on the microbial production of hydrocarbon fuels.